drugset / Trial / NCT07028320
To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk
RandomizedParallel-groupOpen-labelTreatment
Summary
To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women with Osteoporosis at High Fracture Risk
Timeline
- Start
- 2021-12-03
- Primary completion
- 2023-12-30
- Completion
- 2024-05-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alendronic Acid | Small molecule | 70 mg | Oral |
| Subject | SAL056 | Protein / enzyme biologic | 56.5 ug | Subcutaneous |